Merck: new data on HPV vaccine

(CercleFinance.com) - Merck announces that new clinical and real-world data on its 9-valent human papillomavirus (HPV) vaccine, 'Gardasil 9', will be presented at the International Papillomavirus Conference (IPVC) 2024 in Edinburgh.


These data come from two studies looking at the prevalence of oral HPV infection and the impact of HPV-related oropharyngeal and head and neck cancers.

They also underline the importance of HPV vaccination from the age of 9, in both women and men, to prevent these cancers.


Copyright (c) 2024 CercleFinance.com. All rights reserved.